There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Javier Quilez |
| Institution: | Clarivate Analytics |
| Department: | Life Sciences Professional Services |
| Country: | |
| Proposed Analysis: | Amylin is known to play a role in AD pathology. However, the exact structure and role of the amylin pathway in AD is currently not understood. We are working on an NIH-funded (NIH grant R56AG059805) collaborative project with the Boston University to understand the structure and function of amylin pathway in Alzheimer's disease. Our bioinformatics data analysis will be focused on identification of statistical associations of the amylin pathway gene members with clinical features of AD. Specifically, we will first compile a list of genes (100-200 genes) involved in the amylin pathway in normal state and AD through published literature annotation. Next, we will analyze associations of those genes with AD clinical features using ROSMAP data at multiple biological levels: genetic, epigenetic, transcriptional and proteomic. For example, differential expression analysis will show if a gene from the amylin pathway is over- or under-expressed in connection with AD clinical endpoints. Similarly, association analyses will be performed at each biological level: genetic associations (GWAS), epigenetic associations (differential DNA methylation), transcriptional associations (gene differential expression) and proteomic associations (protein differential abundance) for the genes from the amylin pathway with clinical endpoints of interest. This will shed light on the function of amylin pathway in AD and offer potential avenues for the pathway therapeutic use for AD treatment. |
| Additional Investigators |
